## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

#### HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Guidance development**

# FTA Faricimab for wet age-related macular degeneration [ID3898]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

### Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

The committee recognised that the patient population of this appraisal is a protected group under the Equality Act of 2010. This is because visual impairment resulting from wet age-related macular degeneration is recognised as a disability.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No additional equality issues have been raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No additional equality issues have been raised.

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of faricimab for wet age-related

macular degeneration Issue date: June 2022

4.	Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.	
5.	Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
NA.	
7.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Approved by Associate Director (name): Ross Dent

**Date:** 05/05/2022

macular degeneration Issue date: June 2022